Assess patient for urinary tract infection (fever, cloudy urine, frequency, urgency, pain and burning on urination) or other signs of infection at beginning of and throughout therapy.
Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving results.
Monitor intake and output ratios. Fluid intake should be sufficient to maintain urine output of at least 12001500 mL daily.Lab Test Considerations
May produce elevated serum bilirubin, creatinine, BUN, AST, and ALT.
» Monitor CBC and urinalysis periodically throughout therapy. Therapy should be discontinued if blood dyscrasias occur.